GRIN3A
Basic information
Region (hg38): 9:101569352-101738647
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GRIN3A gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 59 | 63 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 11 | 11 | ||||
Total | 0 | 0 | 70 | 3 | 1 |
Variants in GRIN3A
This is a list of pathogenic ClinVar variants found in the GRIN3A region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
9-101573220-G-A | not specified | Uncertain significance (Nov 06, 2023) | ||
9-101573307-C-T | not specified | Uncertain significance (Nov 03, 2023) | ||
9-101573314-C-T | not specified | Uncertain significance (Jun 10, 2022) | ||
9-101573337-T-C | Benign (Aug 10, 2018) | |||
9-101573346-C-T | not specified | Uncertain significance (Dec 03, 2021) | ||
9-101573401-G-A | not specified | Uncertain significance (May 31, 2023) | ||
9-101573421-C-A | not specified | Uncertain significance (Apr 25, 2023) | ||
9-101573422-C-T | not specified | Uncertain significance (Apr 06, 2024) | ||
9-101573437-A-G | Likely benign (Aug 15, 2018) | |||
9-101573454-T-A | not specified | Uncertain significance (Dec 28, 2023) | ||
9-101573485-C-T | not specified | Uncertain significance (Sep 17, 2021) | ||
9-101573494-G-T | not specified | Uncertain significance (Jun 11, 2024) | ||
9-101579261-A-G | not specified | Uncertain significance (Dec 15, 2022) | ||
9-101579352-T-A | not specified | Uncertain significance (Jan 05, 2022) | ||
9-101594414-C-T | not specified | Uncertain significance (Dec 01, 2022) | ||
9-101594473-A-G | not specified | Uncertain significance (Feb 17, 2023) | ||
9-101594522-C-A | not specified | Uncertain significance (Jan 04, 2022) | ||
9-101594675-T-A | not specified | Uncertain significance (Oct 24, 2023) | ||
9-101594726-C-T | not specified | Uncertain significance (Aug 17, 2022) | ||
9-101594735-C-T | not specified | Uncertain significance (Aug 16, 2021) | ||
9-101594767-T-G | not specified | Uncertain significance (Oct 12, 2022) | ||
9-101594773-C-A | not specified | Uncertain significance (Apr 20, 2024) | ||
9-101594777-G-C | not specified | Uncertain significance (Oct 12, 2021) | ||
9-101594782-G-C | not specified | Uncertain significance (Jun 11, 2021) | ||
9-101594836-T-C | not specified | Uncertain significance (Oct 29, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GRIN3A | protein_coding | protein_coding | ENST00000361820 | 9 | 169228 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.453 | 0.547 | 125709 | 0 | 39 | 125748 | 0.000155 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.743 | 547 | 598 | 0.915 | 0.0000323 | 7298 |
Missense in Polyphen | 179 | 234.01 | 0.76491 | 2973 | ||
Synonymous | -0.357 | 247 | 240 | 1.03 | 0.0000132 | 2232 |
Loss of Function | 4.61 | 9 | 40.7 | 0.221 | 0.00000213 | 460 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000485 | 0.000362 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000381 | 0.000381 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000185 | 0.000185 |
Middle Eastern | 0.000381 | 0.000381 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity). {ECO:0000250}.;
- Pathway
- Glutamatergic synapse - Homo sapiens (human);Nicotine addiction - Homo sapiens (human);cAMP signaling pathway - Homo sapiens (human);Amphetamine addiction - Homo sapiens (human);Neuroactive ligand-receptor interaction - Homo sapiens (human);Alcoholism - Homo sapiens (human);Cocaine addiction - Homo sapiens (human);Levomethadyl Acetate Action Action Pathway;Fluoxetine Action Pathway;Citalopram Action Pathway;Escitalopram Action Pathway;Imipramine Action Pathway;Desipramine Action Pathway;Levallorphan Action Pathway;Dimethylthiambutene Action Pathway;Ethylmorphine Action Pathway;Pentazocine Action Pathway;Naltrexone Action Pathway;Buprenorphine Action Pathway;Alvimopan Action Pathway;Naloxone Action Pathway;Dihydromorphine Action Pathway;Methadone Metabolism Pathway;Nicotine Action Pathway;Nalbuphine Action Pathway;Ketobemidone Action Pathway;Lidocaine (Local Anaesthetic) Action Pathway;Mepivacaine Action Pathway;Chloroprocaine Action Pathway;Cocaine Action Pathway;Dibucaine Action Pathway;Levobupivacaine Action Pathway;Benzocaine Action Pathway;Bupivacaine Action Pathway;Levorphanol Action Pathway;Propoxyphene Action Pathway;Tramadol Action Action Pathway;Diphenoxylate Action Pathway;Anileridine Action Pathway;Methadone Action Pathway;Oxycodone Action Pathway;Oxybuprocaine Action Pathway;Prilocaine Action Pathway;Procaine Action Pathway;Proparacaine Action Pathway;Ropivacaine Action Pathway;Codeine Action Pathway;Morphine Action Pathway;Heroin Action Pathway;Alfentanil Action Pathway;Oxymorphone Action Pathway;Hydrocodone Action Pathway;Hydromorphone Action Pathway;Sufentanil Action Pathway;Remifentanil Action Pathway;Fentanyl Action Pathway;Carfentanil Action Pathway;3-Methylthiofentanyl Action Pathway;Methadyl Acetate Action Pathway;Dezocine Action Pathway
(Consensus)
Recessive Scores
- pRec
- 0.110
Intolerance Scores
- loftool
- 0.232
- rvis_EVS
- 0.21
- rvis_percentile_EVS
- 67.53
Haploinsufficiency Scores
- pHI
- 0.430
- hipred
- Y
- hipred_score
- 0.753
- ghis
- 0.538
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.673
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | High | High | High |
Primary Immunodeficiency | High | High | High |
Cancer | High | High | High |
Mouse Genome Informatics
- Gene name
- Grin3a
- Phenotype
- normal phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);
Gene ontology
- Biological process
- calcium ion transport;dendrite development;ionotropic glutamate receptor signaling pathway;response to ethanol;regulation of postsynaptic membrane potential;prepulse inhibition;calcium ion transmembrane transport;regulation of synaptic vesicle exocytosis
- Cellular component
- plasma membrane;postsynaptic density;membrane;integral component of membrane;NMDA selective glutamate receptor complex;cell junction;neuron projection;neuronal cell body;synapse;postsynaptic membrane;glutamatergic synapse
- Molecular function
- NMDA glutamate receptor activity;calcium channel activity;protein binding;glycine binding;identical protein binding;protein phosphatase 2A binding;transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential